Source-grounded facts extracted from MANNKIND CORP's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
MANNKIND CORP reported the first quarter of 2026 results: revenue $90,171.
“386 3 % Furoscix 15,493 — 15,493 N/A V-Go 3,141 4,086 (945 ) (23 %) Collaborations and services 23,515 29,376 (5,861 ) (20 %) Royalties 32,749 30,005 2,744 9 % Total revenues $ 90,171 $ 78,354 $ 11,817 15 % Total revenues for the first quarter of 2026 increased compared to the same period in the prior year due to higher revenue from royalties and commercial”
MANNKIND CORP incurred credit facility of $250.0 million with Blackstone Alternative Credit Advisors LP (as Blackstone Representative) at one, three or six month term SOFR (at the Company’s election), subject to a 2% f maturing August 6, 2030.
“On October 7, 2025, the Company borrowed $250.0 million in delayed draw term loans to fund the Acquisition Price and the scPharma Debt Extinguishment.”
MANNKIND CORP amended credit facility of additional $175.0 million incremental delayed draw term loan with Blackstone Alternative Credit Advisors LP (as Blackstone Representative) at one, three or six month term SOFR (at the Company’s election), subject to a 2% f maturing August 6, 2030.
“Pursuant to the Credit Agreement Amendment, among other things, the Lenders agreed to provide an additional $175.0 million incremental delayed draw term loan solely to finance a portion of the fees, premiums, expenses and other transaction costs incurred in connection with the transactions contemplated by the Merger Agreement”
MANNKIND CORP completed an acquisition involving scPharmaceuticals Inc. for approximately $296.5 million (closed 2025-10-07).
“Share outstanding immediately prior to the Effective Time. The aggregate cash paid by the Company and Purchaser in the Offer and the Merger at the Closing Date was approximately $296.5 million (the “ Acquisition Price ”), which was funded by the Company from its available cash on hand and net proceeds from borrowings under its Credit Agreement (as defined below). As”
Burkhard Blank changed role as Chief Medical Officer and Executive Vice President, Research & Development at MANNKIND CORP.
“On May 9, 2025, MannKind Corporation (the “Company”) and Burkhard Blank, Chief Medical Officer and Executive Vice President, Research & Development, mutually agreed that Mr. Blank would step down from his role as an executive officer of the Company.”
Lauren Sabella departed as Executive Vice President, Operations at MANNKIND CORP.
“On January 2, 2025, Lauren Sabella notified us of her intention to retire from MannKind Corporation (the “Company”), effective July 18, 2025”
Lauren Sabella was appointed as Executive Vice President, Operations at MANNKIND CORP.
“the board of directors of the Company appointed Ms. Sabella as Executive Vice President, Operations, effective January 6, 2025.”
Steven B. Binder departed as Executive Vice President, Special Projects at MANNKIND CORP.
“His employment will end concurrently with his appointment to the Board on the Effective Date.”
Steven B. Binder was appointed as Director at MANNKIND CORP.
“On August 13, 2024, the Board approved the appointment of Steven B. Binder to the Board, effective on the Effective Date.”
Kent Kresa retired as Director at MANNKIND CORP.
“On August 13, 2024, Kent Kresa notified us of his decision to retire from our Board of Directors (the “Board”), effective September 30, 2024 (the “Effective Date”).”
MANNKIND CORP shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2024 at the 2024-05-15 meeting.
“Our stockholders ratified the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. The tabulation of votes on this matter was as follows: shares voted for: 191,751,989; shares voted against: 3,751,421; shares abstaining: 1,962,739; and broker non-votes: 0.”
MANNKIND CORP shareholders approved Advisory vote on executive compensation at the 2024-05-15 meeting.
“Our stockholders approved, on an advisory basis, the compensation of our named executive officers, as disclosed in our definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on April 5, 2024. The tabulation of votes on this matter was as follows: shares voted for: 112,281,517; shares voted against: 11,612,528; shares abstaining: 1,260,654; and broker non-votes: 72,311,450.”
MANNKIND CORP reported the quarter ended March 31, 2024 results: revenue Total revenues of $66M, net income Net income of $11M.
“CORPORATION REPORTS 2024 FIRST QUARTER FINANCIAL RESULTS: PROVIDES CLINICAL DEVELOPMENT UPDATE Conference Call to Begin Today at 5:00 p.m. (ET) • 1Q 2024 Total revenues of $66M; +63% vs. 1Q 2023 • 1Q 2024 Net income of $11M; Non-GAAP net income of $15M • $304M of cash and cash equivalents and investments at March 31, 2024 • In early April, repaid”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.